Ultragenyx Reports Q3 2026 Revenue Growth and Improved Net Loss
Ultragenyx (RARE) reported third-quarter revenue of $173 million, an 8.1% increase year-over-year, driven by international product sales and royalty growth. While CRYSVITA saw a slight decline to $109 million due to Latin American ordering patterns, other products like EVKEEZA grew significantly by over 41%. The company also reported a narrowed net loss of $118 million, down from $180 million in the prior year, largely attributed to reduced research and development spending. To improve profitability, management is implementing restructuring measures including a 20% workforce reduction. The company reaffirmed its 2026 total revenue guidance of $730 million to $760 million. Additionally, Ultragenyx expects significant cash inflows from the sale of two priority review vouchers (PRVs), which are expected to net approximately $350 million after fees.
Tickers: $RARE
Topics: financial guidance net loss improvement revenue growth royalty revenue